Radiopharm Theranostics Ltd has released a press release.
Appendix 4E and Preliminary Final Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Radiopharm Theranostics Limited on 6ix
Earlier from Radiopharm Theranostics
- Radiopharm Theranostics reports Fiscal Year 2025 Financial Results and Business Update
- Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)
- RAD receives IND approval from US FDA for Betabart (RV-01)
- Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board
- Radiopharm Theranostics and Cyclotek Sign Clinical Supply Agreement for ¹⁶¹Tb-KLK3-mAb Phase I Clinical Trial in Australia
Later from Radiopharm Theranostics
- Annual Report for Fiscal Year Ending June 30, 2025 (Form 20-F)
- SPL: Research & Option Agreement with Radiopharm Theranostics
- Radiopharm received approval for RAD 202 trial acceleration
- Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee (DSMC) to Accelerate 177Lu-RAD202 Phase 1 ‘HEAT’ Dose Escalation Clinical Trial
- Trading Halt
Follow Radiopharm Theranostics into a list and get an email when it puts out news.
Follow Radiopharm Theranostics